Management Consulting

Commercial and Vendor Due Diligence

Clear investment analysis and recommendation

Benefit from tailored, complete acquisition insight, investment evaluation and recommendation with our commercial and vendor due diligence. Get in-depth market analysis, competitive landscape and positioning, and business plan assessment from our team of global specialists.

Due diligence designed to meet your business goals

Alira Health delivers analysis and insights to help you clearly assess the benefits and risks of proposed investments with commercial due diligence (CDD) and vendor due diligence (VDD). 

We also conduct careful analysis of biologic product or technology assets for potential partnering or acquisition. When an assessment of CMC aspects of these assets is needed, get technical expertise from our CMC specialists to conduct CMC due diligence to make a well-rounded and informed decision.
By evaluating and forecasting potential outcomes, we’ll help you determine how best to meet your short- and long-term business goals through acquisitions.
We evaluate and prepare companies for:

CDD: Private acquisitions

  • Identification of the target’s sources of competitive advantage
  • Challenges management’s assumptions
  • Verifies top line growth prospects

VDD: Sale or IPO

  • Analysis of its top markets
  • Internal assessment of the firm (Phase I)
  • Ongoing support in the preparation process (Phase II)

Why choose Alira Health?

With Alira Health as your partner, you will benefit from:

  • An experienced team with successful deals worth an accumulated €10B
  • An integrated approach, allowing the team to view assess opportunities from every angle
  • Click here to see how we delivered a recent growth opportunity assessment for a leading pharmaceutical company

Related news

MedTech
News March 3, 2021
The 2021 MedTech Contract Manufacturing Report
Download our latest piece: The 2021 MedTech Contract Manufacturing Report. Learn how despite the ongoing pandemic, the Medical Device and CDMO industries are positioned to perform(...)
M&A
Publications February 28, 2021
What’s most important when selecting a firm for your next transaction?
Market Access MedTech
Multimedia February 26, 2021
Pricing in MedTech: Disentangling the Roles of Payers, DRGs, and Procurement
Join host Kenny Carberry, Associate Director of Clinical Development, Dan Legg, former Director of Clinical Sourcing at Guy’s & St Thomas at the St Thomas Hospital in London and CEO(...)
M&A
Publications February 24, 2021
What You Should Know Before Choosing a Healthcare Transaction Advisory Firm
What’s most important when selecting a firm for your next transaction? Global experience, staff profiles, technical expertise? To learn more download our latest TAD Infographic.
MedTech Pharma
Publications February 8, 2021
Infographic: 2021 Trends in Healthcare
It is no secret that the COVID-19 pandemic has presented new challenges for businesses, and virtual has become the ‘new normal’, including for transactions.
MedTech Pharma
News February 4, 2021
2020 Year in Review
With 2021 in full swing, we want to take a moment to reflect on last year’s achievements and congratulate the entire Alira Health Team for their hard work and dedication to healthcare(...)
Regulatory
News February 2, 2021
We Secured Breakthrough Device Designation from FDA on PEDRA Xauron Perfusion System
We are proud to announce the firm’s Regulatory practice has secured a Breakthrough Device Designation from FDA for the real-time tissue perfusion system, PEDRA Xauron Perfusion System.

Our locations around the globe

Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.